Dose selection for prostate cancer patients based on dose comparison and dose response studies

2000 ◽  
Vol 46 (4) ◽  
pp. 823-832 ◽  
Author(s):  
Gerald E. Hanks ◽  
Alexandra L. Hanlon ◽  
Wayne H. Pinover ◽  
Eric M. Horwitz ◽  
Robert A. Price ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Dose Response ◽  
Dose Selection ◽  
Dose Comparison ◽  
Selection For

Body mass index and mortality in prostate cancer patients: a dose–response meta-analysis

2016 ◽  
Vol 19 (2) ◽  
pp. 122-131 ◽  
Author(s):  
S Zhong ◽  
X Yan ◽  
Y Wu ◽  
X Zhang ◽  
L Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Dose Response ◽  
Meta Analysis

scholarly journals Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis

2018 ◽  
Vol 7 (12) ◽  
pp. R294-R303 ◽  
Author(s):  
Zhen-yu Song ◽  
Qiuming Yao ◽  
Zhiyuan Zhuo ◽  
Zhe Ma ◽  
Gang Chen
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Dose Response ◽  
Protective Factor ◽  
Meta Analysis ◽  
Random Effect Model ◽  
Hydroxyvitamin D ◽  
Risk Of Death ◽  
25 Hydroxyvitamin D

Previous studies investigating the association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer yielded controversial results. We conducted a dose–response meta-analysis to elucidate the relationship. PubMed and EMBASE were searched for eligible studies up to July 15, 2018. We performed a dose–response meta-analysis using random-effect model to calculate the summary hazard ratio (HR) and 95% CI of mortality in patients with prostate cancer. Seven eligible cohort studies with 7808 participants were included. The results indicated that higher vitamin D level could reduce the risk of death among prostate cancer patients. The summary HR of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D level was 0.91, with 95% CI 0.87–0.97, P = 0.002. The HR for all-cause mortality with the increase of 20 nmol/L vitamin D was 0.91 (95% CI: 0.84–0.98, P = 0.01). Sensitivity analysis suggested the pooled HRs were stable and not obviously changed by any single study. No evidence of publications bias was observed. This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document